Earnings Call Intelligence Subscribe
Home › Call Sheets › DHR › Q2'26
Call sheet · Q2'26

Danaher (DHR)

Q2'26 earnings call · held July 21, 2026 · compared with the Q1'26 call · management-credibility review
5/12
Disclosure score
2 high, 5 medium, 1 low flags
Financial quality
Bottom line
The sleeper story is that DHR's vaunted bioprocessing franchise just revealed massive customer concentration risk, with a handful of customers able to crater quarterly results by shifting resin orders. The Street sees 'timing issues' but I see a business with less control over its destiny than the premium multiple implies. Management claims 'very healthy' demand with mid-teens order growth, yet revenue grew low-single and they cut full-year guidance by 200+ bps. The binding constraint isn't demand, it's that DHR has become a hostage to a few large customers' production schedules. Most revealing quote: 'These delays were at our customer's request due to production schedule changes and site readiness challenges.' My view changes if they disclose customer concentration metrics and prove the $100M ships in Q1 2027.

The 30-second version

  • Bioprocessing consumables orders up mid-teens but revenue missed by $50-60M as customers delayed shipments
  • Life Sciences accelerated to 5.5% growth as biotech funding finally converts to orders
  • Management quietly walked back bioprocessing guidance from 'high single' to 'mid-single' for FY26

What changed this quarter

MetricQ1'26Q2'26Change
Core Revenue Growth0.5% (Q1)3% (Q2)+250 bps acceleration
Core Revenue ex-Respiratory3% (Q1)4.5% (Q2)+150 bps acceleration
Adjusted EPS$2.06 (Q1)$1.94 (Q2)Sequential decline but +8% YoY
Free Cash Flow$1.1B (Q1)$1.3B (Q2)+18% sequential improvement
FCF/Net Income Conversion105% (Q1)124% (Q2)+1900 bps improvement
Biotechnology Segment Growth7% (Q1)2.5% (Q2)-450 bps deceleration
Bioprocessing GrowthHigh single (Q1)Low single (Q2)~500 bps miss on consumables
Life Sciences Growth0.5% (Q1)5.5% (Q2)+500 bps acceleration
Diagnostics Growth-4% (Q1)2% (Q2)+600 bps improvement
China GrowthMid-single (Q1)Mid-single (Q2)Stable, double-digit in biotech

Accountability tracked

7 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full DHR Q2'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.